Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

NCT03302247 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Unable to accrue subjects

Conditions

Non Small Cell Lung Cancer Stage IIIB

Interventions

BIOLOGICAL: Nivolumab
DRUG: Nivolumab+Gemcitabine

Sponsor

Fox Chase Cancer Center